We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Unexplained Liver Disease Diagnosed by Whole-Exome Sequencing

By LabMedica International staff writers
Posted on 29 Apr 2019
Print article
Image: The use of WES on adults with liver disease of unknown cause illustrates the potential clinical value of genome rounds in the individual assessment and medical care of patients (Photo courtesy of the Yale School of Medicine / Journal of Hepatology).
Image: The use of WES on adults with liver disease of unknown cause illustrates the potential clinical value of genome rounds in the individual assessment and medical care of patients (Photo courtesy of the Yale School of Medicine / Journal of Hepatology).
A recent paper promoted the use of whole-exome sequencing (WES) to detect and diagnose cases of unexplained liver disease.

Chronic liver disease is a significant health problem affecting more than four million people and leading to over 40,000 deaths annually in the United States alone. It often remains undiagnosed for many years until overt manifestations of chronic liver disease emerge and liver injury has already reached catastrophic proportions.

Adult patients suffering from unexplained liver disease represent an understudied and underserved population, and, furthermore, the use of whole-exome sequencing (WES) to diagnose the disease remains poorly studied.

To correct this deficiency, investigators at Yale School of Medicine (New Haven, CT, USA) performed WES and deep phenotyping of 19 unrelated adult patients with idiopathic liver disease following an ambiguous conventional work-up performed by a hepatologist. WES is a technique for sequencing all the approximately 20,000 human protein-coding genes. It is suitable for both clinical use and translational research studies.

The investigators reported that in five cases, genomic analysis led to diagnosis and informed treatment and management of the disease. For example, in one case, molecular diagnosis enabled initiation of leptin replacement therapy that restored liver function and decreased daily insulin requirements. In two of the cases, a mitochondrial disorder due to a homozygous pathogenic variant enabled initiation of disease preventive measures including supplementation with antioxidants.

"This study provides evidence that a subset of adult patients who suffer from liver disease of indeterminate etiology with or without other comorbidities harbor an underlying Mendelian disorder, which may be unrecognized during their entire childhood until genetic testing is performed," said senior author Dr. Silvia Vilarinho, assistant professor of medicine and pathology at Yale School of Medicine. "Our data highlight the importance of using WES in the investigation of liver disease of unknown cause so that we may start developing an understanding of what clinical presentations or diseases are genetic and may remain undiagnosed until adulthood."

"Advances in human genomics through next generation sequencing technology have created an unprecedented opportunity for genetic investigation and clinical diagnosis," said Dr. Vilarinho. "However, to date, most studies that investigate the use of next generation sequencing technologies in diagnosis and personalized medical care have been performed in either pediatric or cancer patients. The clinical utility of these approaches for a broader spectrum of diseases among adults remains poorly studied."

The WES study was described in the April 1, 2019, online edition of the Journal of Hepatology.

Related Links:
Yale School of Medicine

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Microbiology

view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more

Pathology

view channel
Image: The tool can improve precision oncology by accurately predicting molecular subtypes and therapy responses (Photo courtesy of Shutterstock)

Computational Tool Integrates Transcriptomic Data for Improved Breast Cancer Diagnosis and Treatment

Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.